Growth N. V. Biotech Acquires 150,000 Shares of Radius Health, Inc. (RDUS) Stock
Radius Health, Inc. (NASDAQ:RDUS) major shareholder Growth N. V. Biotech bought 150,000 shares of the stock in a transaction on Thursday, September 14th. The stock was purchased at an average price of $33.45 per share, for a total transaction of $5,017,500.00. Following the completion of the purchase, the insider now directly owns 5,448,799 shares in the company, valued at $182,262,326.55. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of Radius Health, Inc. (NASDAQ RDUS) traded up 1.67% during trading on Friday, hitting $33.54. 2,913,154 shares of the stock were exchanged. The stock’s market cap is $1.46 billion. Radius Health, Inc. has a 52-week low of $31.58 and a 52-week high of $59.22. The firm has a 50 day moving average of $37.54 and a 200-day moving average of $39.19.
Radius Health (NASDAQ:RDUS) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.23). The business had revenue of $0.98 million for the quarter, compared to analyst estimates of $1.96 million. During the same quarter in the prior year, the company earned ($1.01) earnings per share. Equities research analysts anticipate that Radius Health, Inc. will post ($5.58) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Growth N. V. Biotech Acquires 150,000 Shares of Radius Health, Inc. (RDUS) Stock” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/09/15/growth-n-v-biotech-acquires-150000-shares-of-radius-health-inc-rdus-stock.html.
A number of large investors have recently modified their holdings of RDUS. BlackRock Inc. lifted its holdings in Radius Health by 98,245.6% during the first quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock valued at $101,679,000 after purchasing an additional 2,628,070 shares in the last quarter. Farallon Capital Management LLC lifted its holdings in Radius Health by 18.3% during the second quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock valued at $166,731,000 after purchasing an additional 569,300 shares in the last quarter. TimesSquare Capital Management LLC purchased a new position in Radius Health during the second quarter valued at approximately $25,589,000. BB Biotech AG lifted its holdings in Radius Health by 11.0% during the second quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock valued at $227,905,000 after purchasing an additional 498,400 shares in the last quarter. Finally, RA Capital Management LLC purchased a new position in Radius Health during the second quarter valued at approximately $22,486,000.
RDUS has been the topic of several recent analyst reports. Jefferies Group LLC set a $34.00 target price on shares of Radius Health and gave the stock a “hold” rating in a research note on Monday, June 5th. ValuEngine upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. BidaskClub upgraded shares of Radius Health from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Zacks Investment Research upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Finally, Cantor Fitzgerald set a $65.00 target price on shares of Radius Health and gave the stock a “buy” rating in a research note on Monday, May 22nd. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $53.60.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.